significant proportion of the total available drug and therefore have a significant effect on dosing uniformity through the life of the product the solution formulations of the present invention overcome or substantially mitigate such disadvantages use of a larger metering chamber eg 100 u03bcl will generally be preferred we prefer the formulation to contain between 0 5 and 2 w w more preferably between 0 8 and 1 6 w w particularly between 1 0 and 1 6 w w glycerol another range of particular interest is 0 5 1 w w glycerol we especially prefer to use 1 3 w w glycerol we also especially prefer to use 1 0 w w glycerol depending on the final concentration of fluticasone propionate in the formulation the propellant and the precise amount of low volatility component the concentration of solubilisation agent eg ethanol required will vary so as not to suppress the vapour pressure of the propellant to an undesirable extent the amount of ethanol should preferably not exceed around 35 the amount of ethanol will more preferably be in the range 5 to 30 particularly 5 to 20 more particularly 10 to 20 a range of 7 to 16 w w is also particularly.